C4 Therapeutics, Inc.
Clinical trials sponsored by C4 Therapeutics, Inc., explained in plain language.
A biotech company developing targeted protein degradation therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for Tough-to-Treat blood cancers Results expected Sep 2026 (estimated) May already have reported ↗
-
New Two-Drug attack on Hard-to-Treat myeloma enters early human tests
Disease control Recruiting nowThis early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers…
Phase 1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: experimental combo enters phase 2
Disease control Recruiting nowThis study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…
Phase 2 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC